ARS Pharmaceuticals, Inc.
SPRY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671858
No open-market purchases or sales by ARS Pharmaceuticals, Inc. insiders were filed in the last 90 days; 208 institutions reported holding it in 13F filings for Q2 2026, worth $726.0M in total; Third Point is the only superinvestor holding it.
13F holders, Q3 2023
Institutional positions in ARS Pharmaceuticals, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 97
- +5 vs. Q2 2023
- Shares held
- 66.5M
- +11.5M (+20.8%) vs. Q2 2023
- Total value
- $251.6M
- −$117.4M (−31.8%) vs. Q2 2023
- New holders
- 23
- 38 more added
- Sold out
- 18
- 22 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SPRY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 208 | $726.0M |
| Q1 2026 | 203 | $757.5M |
| Q4 2025 | 191 | $1.05B |
| Q3 2025 | 188 | $840.4M |
| Q2 2025 | 188 | $1.48B |
| Q1 2025 | 184 | $958.9M |
| Q4 2024 | 166 | $752.3M |
| Q3 2024 | 151 | $928.4M |
| Q2 2024 | 115 | $533.0M |
| Q1 2024 | 113 | $612.1M |
| Q4 2023 | 100 | $358.5M |
| Q3 2023 | 97 | $251.6M |
| Q2 2023 | 92 | $369.0M |
| Q1 2023 | 90 | $347.7M |
| Q4 2022 | 73 | $427.9M |
| Q3 2022 | 61 | $160.4M |
| Q2 2022 | 64 | $110.5M |
| Q1 2022 | 70 | $94.7M |
| Q4 2021 | 72 | $200.5M |
| Q3 2021 | 74 | $288.4M |
| Q2 2021 | 76 | $864.6M |
| Q1 2021 | 68 | $1.21B |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding ARS Pharmaceuticals, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Resolute Capital Asset Partners LLC | 0 | $0 | 0.00% | −140,000−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −111,900−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −84,808−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −74,621−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −73,400−100.0% | Sold out |
| Shell Asset Management Co | 0 | $0 | 0.00% | −65,322−100.0% | Sold out |
| Jefferies Financial Group Inc. | 0 | $0 | 0.00% | −60,190−100.0% | Sold out |
| Eversept Partners, LP | 0 | $0 | 0.00% | −48,788−100.0% | Sold out |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −37,903−100.0% | Sold out |
| DekaBank Deutsche Girozentrale | 0 | $0 | 0.00% | −35,000−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −22,992−100.0% | Sold out |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −19,944−100.0% | Sold out |
| Price T Rowe Associates Inc | 0 | $0 | 0.00% | −16,537−100.0% | Sold out |
| Stifel Financial Corp | 0 | $0 | 0.00% | −12,327−100.0% | Sold out |
| Aquatic Capital Management LLC | 0 | $0 | 0.00% | −6,900−100.0% | Sold out |